Novo Nordisk Sues USPTO Over AERx Applications
The USPTO has rejected applications from Novo Nordisk for patents relating to its AERx inhaled insulin delivery system, claiming that the patents didn’t bring anything new to the table.
The pharmaceutical giant, however, claims that the office misinterpreted data, evidence and legislation, according to Danish newspaper Børsen.
Novo Nordisk said it had...
To view the full article, register now.